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Abstract Glycation ofα-crystallin is responsible for age- and
diabetic-related cataracts, which are the main cause of blind-
ness worldwide. We optimized the method of identification of
lysine residues prone to glycation using the combination of
LC-MS, isotopic labeling, and modified synthetic peptide
standards with the glycated lysine derivative (Fmoc-Lys(i,i-
Fru,Boc)-OH). The in vitro glycation of bovine lens α-
crystallin was conducted by optimized method with the equi-
molar mixture of [12C6]- and [
13C6]D-glucose. The in vivo
glycation was studied on human lens crystallin. The glycated
protein was subjected to proteolysis and analyzed using LC-
MS. The results of in vitro and in vivo glycation of α-
crystallin reveal a different distribution of the modified lysine
residues. More Amadori products were detected as a result of
the in vitro reaction due to forced glycation conditions. The
developed method allowed us to identify the glycation sites in
crystallin from eye lenses obtained from patients suffering
from the cataract. We identified K166 in the A chain and
K166 in the B chain of α-crystallin as major glycation sites
during the in vitro reaction. We found also two in vivo
glycated lysine residues: K92 in the B chain and K166 in
the A chain, which are known as locations for Amadori
products. These modification sites were confirmed by the
LC-MS experiment using two synthetic standards. This study
demonstrates the applicability of the LC-MS methods com-
bined with the isotopic labeling and synthetic peptide stan-
dards for analysis of post-translational modifications in the
biological material.
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Introduction
Alpha-crystallin is a dominant protein of the mammalian eye
lenses, essential for the maintenance of the transparency and
its refractive properties [1]. It consists of two related subunits:
αA and αB, with about 55 % sequence similarity [2]. These
subunits occur mainly as a heterogeneous complex within
mass range of approximately 600–800 kDa (known as a poly-
disperse oligomer). The αA subunit is specific for lenses,
whereas the αB subunit appears also in other tissues, includ-
ing the retina, heart, brain, lung, and skeletal muscle [3].
Moreover, increased levels of αB-crystallin are typical for
many neurodegenerative disorders, diabetic conditions, and
tumors [4].
The α-crystallin belongs to a small heat-shock proteins
(sHsp) family of intracellular molecular chaperone proteins
[5]. As a molecular chaperone, it protects other lens proteins
from the effects of UV irradiation, high temperature, and
chemical compounds, preventing the aggregation and dena-
turation of target proteins [6]. Indeed, it binds to early, partial-
ly unfolded intermediate states of other proteins by hydropho-
bic binding sites [7]. This reversible interaction reduces the
formation of aggregation-prone late unfolding intermediates
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[8, 9]. It has been found that two peptides withinαA- and αB-
crystallin act as molecular chaperones, similar to the native
molecules. The smallest peptide fragments that display a max-
imal antiaggregation activity are [70–88] in αA-crystallin
(mini-αA-crystallin) and [73–92] in αB-crystallin (mini-αB-
crystallin) [10].
Due to the fact that the lens crystallins are long-lived pro-
teins, they undergo various post-translational modifications
including oxidation, glycation, isomerization, deamidation,
racemization, and truncation. These modifications are the ma-
jor factors which promote protein aggregation and may con-
tribute to progression of lens opacification. Among these
modifications, the non-enzymatic reaction ofα-crystallin with
reducing sugars has been reported to be one of the most sig-
nificant factors leading to the age-related cataract, in particular
for diabetic patients [11–13]. This reaction, known as
glycation or Maillard reaction (see Electronic Supplementary
Material (ESM) Fig. S1), involves free amino groups in pro-
teins (lysine or the N-terminal amino acid) and the aldehyde
group of the aldose sugar, in that case glucose. The first stable
product is the ketoamine which is also called the Amadori
product. This product finally transforms into stable modifica-
tions on proteins that are known as advanced glycation end
products (AGEs). The presence of AGEs leads to conforma-
tional changes and alterations of the protein-protein and
protein-water interactions, affecting the lens protein
crosslinking and aggregation, and, in consequence, the trans-
parency of the lens [14].
Lysine residues are known to be the major glycation sites in
proteins. Human, bovine, and rat αA-crystallin and αB-
crystallin contain 7 and 10 lysine residues, respectively. Al-
though all the lysine residues are potential glycation sites,
studies have shown regioselectivity in the glycation of various
lysine residues [15, 16].
In the first report, where glycation sites ofα-crystallin have
been detected, Abraham et al. studied in vitro glycation of the
calf lens [15]. Two different approaches were applied to de-
termine the sites of the reaction. In the first approach, α-
crystallin was labeled by 14C glucose, followed by digestion
by chymotrypsin. The resulting peptides were purified by RP
HPLC. In the second approach, α-crystallin was modified by
non-labeled glucose and after proteolysis glycated peptides
were subjected to phenylboronate affinity chromatography
and RP HPLC. The major reaction sites were identified by
FAB-MS as K11 and K78 in αA-crystallin and K90 and/or
K92 in αB-crystallin.
The second study, also presented by Abraham et al. [17],
concerned a connection between mutation in the glycation site,
i.e., a change from the lysine to the threonine residue, and the
level of protein glycation after in vitro reaction with 100 mM
fructose. The experiment confirmed that K11 is the major
glycation site in αA-crystallin because there was a 33 % de-
crease in glycation after K11T mutation, whereas the mutation
of K78 (K78T) led to only a 17 % decrease in glycation level.
K166 also seems to be an important glycation site because a
27 % decrease in glycation was observed in K166T. The resi-
dues K11, K78, and K166 inαA-crystallin (K78 being the least
reactive of the three) and K90, K92, and K166 in αB-crystallin
were indicated to be the major glycation sites when ascorbic
acid was used as a glycating agent [16].
The research concerning glycation in vivo of α-crystallin
[18] was conducted on urea-soluble lens protein fractions
from the cataract lenses of 1-month-old Sprague-Dawley rats.
This material was treated with 1 M [3H]NaBH4. Isolated high
molecular weight (HMW) aggregates were separated by mo-
lecular sieve HPLC method. After reduction with β-
mercaptoethanol, they were subjected to polyacrylamide gel
electrophoresis and proteolysis with chymotrypsin and tryp-
sin. The glycated peptides were enriched by boronate affinity
chromatography, purified byRPHPLC, and the fractions were
examined for radioactivity. These studies indicated that K11,
K78, and K166 in αA-crystallin and K166 in αB-crystallin
were the most frequently modified residues in the αA- and
αB-crystallin chains.
In this report, we attempted to identify the lysine residues
which are the most susceptible to glycation during the model
in vitro studies, as well as in vivo in patients suffering from
cataract. Diabetes is a major risk factor for this disease, leading
ultimately to the loss of vision [19–21]. The identification of
modified residues is crucial in studies of the post-translational
modifications (PTM) in α-crystallin for the future recognition
of the mechanism of diabetic complications combined with
cataract changes. For this purpose, the whole trypsin hydroly-
sate of the biological material from human lenses was ana-
lyzed using LC-MS. We also synthesized glycated standards,
using a method developed by us, based on Fmoc-Lys(i,i-Fru,
Boc)-OH [22]. A mixture of the standards and the obtained
hydrolysate of lenses were subjected to the LC-MS analysis.
These results were compared with the data obtained after
in vitro glycation using the mixture of [12C6]- and [
13C6]-iso-
topically labeled D-glucose, which was applied at high,
nonphysiological concentrations. This approach was previ-
ously developed by us for detection of early [23–25] as well
as advanced glycation sites [26].
The advantage of the presented method is the fast, fully
tested procedure for confirmation of detected compound in
biological samples. It is worth noting that preparation of the
biological material has been also significantly simplified.
Materials and methods
Reagents
Reagents including α-crystallin isolated from bovine eye
lens, isotopically labeled [13C6]D-glucose, 99 %
13C,
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[12C6]D-glucose, O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate (TCTU), dithiothre-
i tol (DTT), ammonium bicarbonate (NH4HCO3),
trifluoroacetic acid (TFA), triisopropylsilane (TIS), and
solvents: N,N-dimethylformamide (DMF), dichlorometh-
ane (DCM), methanol (MeOH), and acetonitrile of the
LC-MS grade were purchased from Sigma-Aldrich and
were used without further purification.
Trypsin (from bovine pancreas, TPCK treated, Sigma-
Aldrich) was dissolved in purified water at the concentration
of 1 mg/1ml and used for the described experiments. The Sep-
Pak C18 Plus Light Cartridges (Waters) were used for
desalting (parameters: 130 mg sorbent per cartridge, 55–
105 μm particle size, 50/pk). For dialysis, a Pierce SnakeSkin
Pleated Dialysis Tubing was used (Thermo Scientific, 10 K
MWCO). Formic acid at the concentration of 99 % was pur-
chased from Merck.
Biological samples of lens crystallin proteins obtained
from the human patients suffering from diabetes were
supplied by the eye clinic Lexum (Wroclaw, Poland).
The fragmented lens particles are a waste material after
the regular (routine) cataract surgery. Obtained materials
were intended for disposal. Moreover, the fragmented por-
tions of lens originating from different patients were col-
lected in one dialysis cassette so the presented results
cannot be assigned to a specific patient. The cataract op-
eration is conducted in the operating room at the aseptic
conditions. The operation consists in grinding patient`s
eye lens with ultrasounds. During the operation, the Ring-
er liquid is being consistently infused. The fragmented
lens particles are aspirated to disposable, sterile cases
filled with liquid. Cases and drains used for the operation
are an integrated circuit that is not contaminated with any
biological material. Samples of crystallin were delivered
in physiological saline solution at the NaCl concentration
of 0.9 %.
An amino acids sequence of chains of bovine and human
alpha-crystallin was in accordance with the UniProt
Knowledgebase (UniProtKB).
Experiment A (glycation in vitro)
Sample of α-crystallin was glycated according to the opti-
mized method published previously [23, 26, 27] using an
equimolar mixture of [12C6]D-glucose and [
13C6]D-glucose.
Samples were mixed with these sugars and dissolved in water
to give a protein to sugar molar ratio of 1:1000 (experiments
A1–A4). Results of additional experiments with the use a
protein to sugar molar ratio 1:500 (experiments A5, A6),
and 1:370 (experiments A7, A8) are presented in Online Re-
course. The samples were lyophilized. To achieve the
glycation, the dry lyophilisate was heated at 80 °C for 25 min.
Dialysis
Samples were dissolved and dialyzed using a SnakeSkin Di-
alysis Tubing for 24 h.
Reduction
The glycated protein (0.5 mg) was dissolved in 50 mM
NH4HCO3 buffer solution. A solution of 200 μl DTT
(200 mM) was added and then the mixture was incubated at
60° for 30 min.
Proteolysis
The trypsin solution was added to the mixture of the reduced
protein (0.5 mg) to obtain the 1:10 (A1–A3 and A5–A8) or
alternatively 1:1 (A4) enzyme:substrate mass ratio. The mix-
ture was incubated at 37 °C for 24 h. Digestion was terminated
by the addition of 10 μl of formic acid. The samples were
subjected to LC-MS analysis.
Experiment B (glycation in vivo)
The sample B, which contained the biological material obtain-
ed from 11 human lenses in the volume of 600 ml of 0.9 %
saline solution, was first centrifuged for 20 min (14,000 RPM,
16,873×g) to separate the insoluble precipitate from the super-
natant (see Fig. 1, B1). Four 100-ml portions of the superna-
tant were taken for further analysis. Four different strategies
were applied to compare the obtained fragments. The experi-
ments consisted of the same steps which were performed in
different order. The amounts of reagents (trypsin and dithio-
threitol) were calculated on the basis of the amount of proteins
isolated from one lens according to the literature [28].
Reduction
The lyophilized samples were dissolved in 50 mMNH4HCO3
buffer solution (3 ml). The solution of DTT (45 μl, 45 mM, in
water) was added and then the mixture was incubated at 50 °C
for 15 min.
Proteolysis
The trypsin solution was added to the mixture of the reduced
proteins to obtain the 1:10 enzyme:substrate mass ratio. The
mixture was incubated at 37 °C for 24 h. Digestion was ter-
minated by the addition of 10 μl of formic acid.
Desalting
The samples (after enzymatic hydrolysis) were lyophilized
and then desalted on an RP-C18 cartridge (Sep-Pak). The
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hydrolysates were eluted by 60 % acetonitrile in water. The
sample after lyophilization was subjected to the LC-MS
analysis.
The sample B2 was treated in the same way as the precip-
itate (B1). In the case of B3, the procedure was preceded by
dialysis whereas two samples (B4–B5) were first lyophilized.
All the samples were subjected to reduction by DTT (100 μl,
45 mM, in water), hydrolysis, and desalting on an RP car-
tridge, and analyzed by LC-MS.
The procedures for preparation of two additional portion of
biological materials (experiments: C and D) obtained from the
patients suffering from cataract after cataract surgery are pre-
sented in ESM (Fig. S3 and S4).
Synthesis of glycated peptides
The synthesis of two glycated peptides of glycated human α-
c r y s t a l l i n ( V K ( F r u ) V L G D V I E V H GK a n d
EEK(Fru)PTSAPSS) was performed according to the Fmoc
protocol using the Wang resin. The sequences of these pep-
tides were [91–103] from the αB chain and [164–173] from
the αA chain. The synthesis was conducted using synthetic
protected fructolysine Fmoc-Lys(i,i-Fru,Boc)-OH (ESM
Fig. S2) obtained by procedure described previously by
Stefanowicz et al. [23]. TCTUwas used as a coupling reagent.
The peptides were cleaved from the resin using TFA/water/
TIS (90:5:5, v/v) for 8 h at a room temperature and precipitated
with cold diethyl ether.
LC-MS analyses of biological material and synthetic peptides
The first LC-MS experiment was conducted for the synthetic
peptides. Then the trypsin hydrolysate of human lens
crystallin from the B3 sample was analyzed. Finally, this hy-
drolysate was mixed with two synthetic peptides for a third
LC-MS experiment.
LC-MS measurements
The LC-MS analyses were performed in the Laboratory of
Mass Spectrometry at the Faculty of Chemistry, Universi-








































Fig. 1 Diagram of the procedures for preparation of the biological material for LC-MS analysis (B1–B5)
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coupled to a micrOTOF-Q mass spectrometer (Bruker
Daltonics, Germany). The micrOTOF-Q instrument
equipped with an ESI source with an ion funnel was op-
erated in the positive ion mode and calibrated before each
analysis with the Tunemix™ mixture (Bruker Daltonics,
Germany) in a quadratic method. Argon was used as a
collision gas. For separation, an Aeris PEPTIDE,
Phenomenex (50×2.1 mm, 3.6 μm) column was used
with elution gradient of 0–100 % B in A (A=0.1 %
HCOOH in water; B=0.1 % HCOOH in acetonitrile) over
62 min (flow rate 0.05 ml/min, room temperature). In LC-
MS/MS experiments, the collision energy eV was selected
after CID studies on the synthetic model peptides.
MS/MS analysis
The FT-ICR instrument (Bruker Daltonics, Germany)
equipped with an ESI source with an ion funnel was operated
in the positive ion mode and calibrated before each analysis
with the Tunemix™ mixture (Bruker Daltonics, Germany) in
a quadratic method. Argon was used as a collision gas. In MS/
MS experiments, the collision energy (15 eV) was optimized
for the best fragmentation.
Data analysis
The mass list generated by a DataAnalysis program, 4.0
(Bruker, Germany) was analyzed using a home-developed
software written in JAVA. The procedure is based on
searching for pairs of ions (light and heavy forms of the
Amadori product) of equal abundances in which the differ-
ence of monoisotopic mass equals 1.003×n, where n is the
number of carbon atoms derived from glucose. The accepted
error of mass difference was below 0.02 Da, while the accept-
ed difference of abundances was below 10 %. The program
calculates the theoretical masses of peptides obtained from in
silico digestion taking into consideration the defined specific-
ity of trypsin. Then it assigns the peptide sequences to peaks
from the scans of the LC-MS data set and generates lists of
potential glycated peptides using mass shifts characteristic for
early glycation products.
Results and discussion
The products of reaction of α-crystallin with D-glucose were
analyzed for both types of glycation: in vitro and in vivo. The
results of the in vivo glycation (experiments: B, C, D) were
compared with the data obtained from the in vitro glycation
using high concentrations of isotopically labeled sugar (exper-
iments: A1–A8) and in the last stage confirmed by the syn-
thetic glycated standards.
Study on in vitro glycation of α-crystallin
(experiments A1–A8)
The first stage of our study was the in vitro glycation of com-
mercially available crystallin from bovine eye lens with
[13C6]D-glucose (
13C6 Glc). It was conducted to create a ref-
erence data set for glycation in vivo required to compare the
process of glycation at the physiological and forced condi-
tions. The samples of α-crystallin were mixed with an equi-
molar mixture of [12C6]D-glucose and [
13C6]D-glucose at the
different molar protein to glucose ratios: 1:370 (A7–A8),
1:500 (A5–A6), and 1:1000 (A1–A4). The glycation was con-
ducted by the optimized procedure published by us [26, 27].
The samples were dialysed, reduced, and hydrolysed by tryp-
sin. The hydrolysates were subjected to LC-MS experiments.
The obtained data sets were analyzed by a program written in
Java. The identification of the glycated peptides was based on
a characteristic isotopic distribution. The isotope labeling
leads to a characteristic signal distribution in mass spectra—
the doublet pattern of glycated peptides with the equal inten-
sity and a mass difference of 6.018 Da, which simplifies the
interpretation of the LC-MS results.
The number of identified glycation sites (Table 1 and ESM
Tables S1 to S7) depends on the protein to glucose ratio. In the
in vitro data set for monoglycated peptides (containing one
lysine residue), K166 from the αA chain and K166 from the
αB chain occur the most frequently (Fig. 2). The occurrence is
based on the number of detected peptide fragments in eight
conducted experiments (A1–A8). Other lysine residues which
are located in the αA chain: K70, K88, K99, and K145 were
less frequently glycated. For the αB chain, the lysine residues
K103, K121, and K150 are also identified as potential
glycation sites. Taking into account the concentration of D-
glucose, we observed that in fragments with one potential
glycation site, K70 and K99 from the αA chain and K103
and K166 from the αB chain dominate for samples A7 and
A8 (ESM Tables S6 and S7). In the case of samples A1–A6,
the most prevalent sites are: K70, K99, and K166 from theαA
chain and K166 from the αB chain (Table 1 and ESM
Tables S3 to S7).
According to the trypsin specificity, all the fragments could
contain only one unmodified lysine residue, however, we ob-
served several peptide fragments resulting from incomplete
proteolysis. In this case, the increase in glucose concentration
led to a significant limitation of the number of potential cleav-
age sites (K and R) due to the fact that the Amadori product on
lysine residue inhibits the trypsin action.
In the case of K88 and K99, we can distinguish fragments
with K99 glycated, however, there are multiple fragments con-
taining both these lysine residues with only one glycation site.
Table 1 presents results from experiment A1 for glycation
occurring at the protein to D-glucose 1:1000 molar ratio. The
obtained results revealed the six most frequently glycated
In vitro and in vivo modification of sites in glycated crystallin 2561
lysines. Three of them, K70, K88/K99, and K166 are located
in the αA chain sequences [66–78]/[55–78], [79–103]/[79–
112]/[79–116], and [158–173], respectively. Three others
are: K90/K92/K103, K103, and K150/K166/K174 in the frag-
ments of the sequence [83–116]/[83–120], [91–116]/[93–
116]/[93–120], and [150–175]/[158–174]/[158–175] in the
αB chain.
The characteristic isotopic distribution for pair of signals
from the [12C6]- and [
13C6]-Amadori products, their identical
retention times, and the identical intensities of extracted ion
chromatograms (XIC) were very strict criteria for examina-
tion of the glycated compounds. The reproducibility of our
experimental results is very high which may be related to the
presence of only one pure protein in the reaction mixture
facilitating the interpretation of the LC-MS data.
The main outcomes of these experiments are:
& The LC-MS method was combined with a stable iso-
tope labeling showed the regioselectivity of glycation
during the in vitro conditions. Redistribution of mod-
ified lysine residues depends on concentration of D-
glucose.
& We identified fragments of glycated peptides correspond-
ing to the sites of α-crystallin most easily modified during
presented model experiments with the using D-glucose at
high, nonphysiological concentrations.
& In the highest concentration of D-glucose six lysine resi-
dues occur generally: K70, K88/K99, and K166 (αA
chain); K90/K92/K103, K103, and K150/K166/K174
(αB chain).
Table 1 The glycated fragments identified in experiment A1 (Materials and methods)
Observed m/z z Found MW Calc. MW RTa [min] Sequence AA
601.9697 3 1802.8856 1802.8898 18–19 [158–173] α-crystallin A K166
626.3465 5 3126.6934 3126.6772 18–19 [150–175] α-crystallin Ba K150, K166, K174
704.7314 3 2111.1707 2111.1838 18–19 [158–175] α-crystallin B K166, K174
1137.6215 2 2273.2273 2273.2366 18–19 [158–175] α-crystallin Ba K166, K174
496.7779 4 1983.0803 1983.0888 19–20 [158–174] α-crystallin B K166
568.3147 5 2836.5344 2836.5294 19–20 [150–174] α-crystallin B K150, K166
662.0344 3 1983.0797 1983.0888 19–20 [158–174] α-crystallin B K166
704.7335 3 2111.1770 2111.1838 19–20 [158–175] α-crystallin B K166, K174
710.1376 4 2836.5191 2836.5294 19–20 [150–174] α-crystallin B K150, K166
902.4492 2 1802.8827 1802.8898 19–20 [158–173] α-crystallin A K166
992.5451 2 1983.0745 1983.0888 19–20 [158–174] α-crystallin B K166
614.8909 5 3069.4154 3069.4177 20–21 [89–112] α-crystallin A K99
662.0318 3 1983.0719 1983.0888 20–21 [158–174] α-crystallin B K166
688.3538 2 1374.6919 1374.7031 20–21 [83–92] α-crystallin B K90
590.4948 5 2947.4349 2947.4424 21 –22 [93–116] α-crystallin B K103
635.9284 5 3174.6029 3174.6058 21–22 [91–116] α-crystallin B K103
728.7490 5 3638.7059 3638.6887 21–22 [89–116] α-crystallin A K99
704.3482 5 3516.7019 3516.7134 22–23 [93–120] α-crystallin B K103
575.6418 3 1723.9019 1723.8992 23–24 [70–82] α-crystallin B K72
691.3567 6 4142.0932 4142.0821 25–26 [83–116] α-crystallin B K90, K92, K103
786.2351 6 4711.3636 4711.3532 25–26 [83–120] α-crystallin B K90, K92, K103
788.8895 4 3151.5267 3151.5211 26–27 [79–103] α-crystallin A K88, K99
845.6076 5 4222.9989 4222.9944 26–27 [79–112] α-crystallin A K88, K99
959.4628 5 4792.2749 4792.2655 26–27 [79–116] α-crystallin A K88, K99
1051.5157 3 3151.5236 3151.5211 26–27 [79–103] α-crystallin A K88, K99
1056.7610 4 4223.0127 4222.9944 26–27 [79–112] α-crystallin A K88, K99
581.9815 3 1742.9210 1742.9091 27–28 [66–78] α-crystallin A K70
1308.6524 2 2615.2891 2615.2755 28–29 [79–99] α-crystallin A K88
967.5204 3 2899.5377 2899.5179 30–31 [55–78] α-crystallin A K70
AA potential glycated lysine residues
a Diglycated peptides. Retention time range used for averaging mass spectra [min]. Details of LC-MS are described in BMaterials and methods^
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Study on in vivo glycation of α-crystallin (experiments B–D)
In the second stage of the project, we attempted to identify the
lysine residues in both αA- and αB-crystallin that easily un-
dergo glycation in lenses from the patients suffering from
cataract. The biological material originating from different
patients has been provided in a collective package so we could
not relate the degree of modification ofαA- and αB-crystallin
to the age and severity of diabetes. The biological material
was delivered in three portions containing 1, 2, and 11 lenses.
The mixture of proteins from human lenses was treated by
different protocols described in BMaterials and methods^
(see also in Online Resource for more details for
experiments C and D). All the protocols include three main
steps: dialysis/desalting, reduction, and enzymatic hydrolysis
using trypsin, conducted in different order. The largest number
of experiments was carried out for the sample (B) because it
contained the biological material obtained from 11 lenses. The
amount of reagents for reduction of the disulfide bridges and
hydrolysis was calculated in relation to the proteins content in
one lens according to the literature [28]. The preparation of the
biological material was optimized to obtain the largest number
of the modified peptides. The insoluble part of the biological
material (precipitate) was separated by centrifugation and then
subjected to a separate analysis. The supernatant was divided
and analyzed according to the protocol presented in Fig. 1.
Because of a high concentration of salt, two of the samples
were subjected to dialysis at different stages of the isolation
procedure. In these five experiments, each of the two identi-
fied peptide fragments was found in at least three analyses
(Table 2). The retention times of three modified fragments
found were identical with the results acquired from the
in vitro glycation analysis. Due to the very strict criteria for
examination of glycated compounds, the extracted ion chro-
matogram was created to prove that the retention times are the
same. To confirm the authenticity of the other unmodified
fragments, MS/MS analyses for selected fragments [55–65]
αA chain, [146–157] αA chain, and [57–69] αB chain were
Fig. 2 The scheme of glycated
lysine residues in αA- and αB-
crystallin on the basis of
occurrence of the monoglycated
peptides with modification in data
set from in vitro experiment
Table 2 The list of identified glycated peptides in three samples (B, C, D) of the biological material (Materials and methods)
Sample Observed M/Z z Found Mw Calc. MW RTa [min] Sequence AA
B1 597.7781 2 1193.5405 1193.5299 17–18 [164–173] α-crystallin A chain K166
B2 597.7771 2 1193.5385 1193.5299 20–21 [164–173] α-crystallin A chain K166
777.9455 2 1553.8753 1553.8665 23–24 [91–103] α-crystallin B chain K92
B3 777.9481 2 1553.8805 1553.8665 23–24 [91–103] α-crystallin B chain K92
B4 398.8547 3 1193.5406 1193.5299 20–24 [164–173] α-crystallin A chain K166
777.9336 2 1553.8515 1553.8665 23–24 [91–103] α-crystallin B chain K92
B5 398.8537 3 1193.5376 1193.5299 22–23 [164–173] α-crystallin A chain K166
C2 1194.5463 1 1193.5385 1193.5299 19–20 [164–173] α-crystallin A chain K166
777.9443 2 1553.8729 1553.8665 23–24 [91–103] α-crystallin B chain K92
785.3809 4 3137.4923 3137.5054 29–30 [79–103] α-crystallin A chain K88, K99
D1 777.9354 2 1553.8551 1553.8665 23–24 [91–103] α-crystallin B chain K92
D2 1194.5477 1 1193.5399 1193.5299 20–21 [164–173] α-crystallin A chain K166
AA potential glycated lysine residues
a Retention time range used for averaging mass spectra [min]. Details of LC-MS are described in BMaterials and methods^
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carried out and the results were in agreement with the predict-
ed fragmentation patterns. The fragmentation spectra con-
firmed the sequences of these fragments. The representative
MS/MS spectra for three selected fragments of αA- and αB-
crystallin are presented in Figs. S7, S8, S9 in the ESM.
For sample C, the procedure C1 based on first isolating of
proteins using RP cartridge Sep-Pak and then reduction and
hydrolysis did not provide as many fragments of the modified
peptides as the procedure C2. We observed a significant loss
of fragments due to the irreversible absorption on the station-
ary phase. The LC-MS analysis of desalted samples C1
showed a low intensity of signals corresponding to the pro-
teins. The MS spectrum of αB crystallin is presented in ESM
Fig. S5. Three modified fragments (Table 2) were found in the
LC-MS analysis of the samples prepared by a second method
(C2). The representative chromatogram obtained for sample
C2 is presented in ESM Fig. S6. The most abundant signal
corresponds to [91–103]αB-crystallin, but the intensity of the
glycated peptide signals was not sufficient to perform frag-
mentation experiments.
Sample D consisting of two lenses was divided into three
different portions. The analyses of samples D1 and D2, which
contained the soluble and insoluble parts of the biological
material, respectively, were performed according to the same
procedure as described for sample C2. In contrast, the first
step of lyophilization was omitted for sample D2. The sample
was adjusted to pH 8 using 50 mMNH4HCO3 buffer solution
and then reduction and hydrolysis were carried out. The ob-
tained results are presented in Table 2. In this experiment, only
one modified fragment [91–103] from αB-crystallin was
found in sample D1. The results acquired from studies on
two lenses provided less information on the modified frag-
ments, which could be correlated with the severity of diabetes
and the age of patients.
The main outcomes of these experiments are:
& According to the results of several experiments, from the
set of the available lysine residues the most frequently
glycated are the ones at positions: K88/K99 and K166 in
the αA chain and K92 in the αB chain.
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XIC 777.9±0.05 for trypsin hydrolyzate of human lens crystallin
Fig. 3 The comparison of XIC
andmass spectra for three LC-MS
analyses (see BMaterials and
methods^ for details) on the
glycated peptide [91–103] from
the αB chain
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& In the analyzed mass spectra, the intensity of signals cor-
responding to glycated peptide [91–103] αB chain with
K92 was the highest in comparison to other modified
fragments.
& The obtained results are consistent with the literature data
for the in vivo [18] and in vitro glycation [15–17].
Application of the synthetic glycated standards for analysis
of the Amadori products in the biological material
The third step of our analysis was a verification of structure for
the glycated peptides identified in the second stage of our
research. For this purpose, the synthesis of two glycated pep-
tides (tryptic fragments of glycated human α-crystallin) was
performed. The sequences of these peptides were [91–103] of
the αB chain and [164–173] of the αA chain. The synthesis
was conducted according to the procedure described by us
previously, using fully protected synthetic fructolysine
Fmoc-Lys(i,i-Fru,Boc)-OH [22].
According to the literature [29], the sequencing of peptides
with the Amadori products by collision-induced dissociation
results in dissociation of the weakest bonds. The conse-
quences are neutral losses from the hexose moiety or elimina-
tion of the whole hexose moiety before dissociation of any
peptide bond. Therefore, the obtained MS spectra are compli-
cated and difficult to interpret. The elimination of the sugar
moiety from an Amadori product may also result in an incor-
rect identification of the modification site. Moreover, for the
studied native hydrolysates, the intensity of detected signals
was really low. Due to these facts, the application of MS/MS
techniques for identification of the modification location was
unpractical. Many overlapping MS signals with a similar m/z
ratio further complicate interpretation of the data.
For the above-mentioned reasons, the LC-MS method was
used to confirm the authenticity of two selected glycated pep-
tides. At first, we conducted an LC-MS experiment for the
synthetic native peptide. Then the trypsin hydrolysate of hu-
man lens crystallin (B3) was analyzed using the same gradient
conditions of LC-MS. Next, the hydrolysate was mixed with
two synthetic native peptides for another LC-MS experiment.
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XIC 597.8±0.05 for trypsin hydrolyzate of human lens crystallin
Fig. 4 The comparison of XIC
andmass spectra for three LC-MS
analyses (see BMaterials and
methods^ for details) on the
glycated peptide [164–173] from
the αA chain
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As a result, we detected these compounds in synthetic native
forms, in hydrolysate, and the mixture with different intensi-
ties of XIC and signals in the mass spectrum. The intensities of
peaks in chromatograms and mass spectra corresponding to
both peptides increased in the third experiment, which is pre-
sented in Figs. 3 and 4.
It is worth noting that the retention times during LC-MS
analysis of the analyzed compounds were nearly identical in
comparison with the retention time obtained for the native
hydrolysate. Such parameters as mass accuracy, intensities
of XIC, and retention times confirmed the locations of modi-
fication sites. It also validated our results for these extremely
complex mixtures of the biological material.
Conclusions
Our results confirmed the regiospecificity of glycation at dif-
ferent conditions. The in vitro experiments with the use of
isotope labeling and LC-MS indicated many reaction sites.
The distribution of these sites is slightly different for various
concentrations of [12C6]- and [
13C6]D-glucose. In this data set,
considered for monoglycated peptides with one reaction site,
glycation at lysine residues: K166 of the αA chain and K166
of theαB chain generally occurs. These lysine residues are the
most susceptible for glycation at high glucose concentrations.
In the experiment conducted for the in vivo glycation, we
detected a lower amount of compounds than in the first stage
of our research. We confirmed the identity of two peptides
with the Amadori products using the synthetic models in
LC-MS analyses: [91–103] αB chain and [164–173] αA
chain.
These products occurred in each performed analysis of the
biological material from different patients suffering from cat-
aract. The detected lysine residues: K92 in the αB chain and
K166 in the αA chain are the most frequently glycated during
the disease process. The confirmation of these glycation sites
may allow for a future quantification of the detected frag-
ments. This result is essential for understanding the modifica-
tionmechanism inα-crystallin during age-related and diabetic
cataract. The verification of the disease history with these data
can present the effect of diabetic conditions and age-related
changes on the modification of α-crystallin. Such a method
may be also used for quantitative determination of advanced
glycation end products. For this purpose, new isotopically
labeled peptide derivatives should be prepared.
The advantages of the presented method include the reac-
tion rate and simplicity of the analysis by using the few steps:
dialysis, reduction, proteolysis, and LC-MS analysis. In the
proposed methods, the enrichment of the glycated samples is
not necessary. The new methods for analysis of the in vivo
glycation were optimized to obtain most of the glycated
fragments. All the procedures for checking the authenticity
of identified glycated peptides: the synthesis of the standards
and the in vitro glycation, were thoroughly tested before [26,
27, 22].
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